-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

617A.O2.6 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
AML, Biological, Adult, Animal models, Non-Biological, Diseases, Therapies, checkpoint inhibitors, Pediatric, chemotherapy, Biological Processes, Technology and Procedures, epigenetics, cytogenetics, Study Population, genomics, Clinically relevant, genetic profiling, Myeloid Malignancies, hematopoiesis, pharmacology, flow cytometry, immune mechanism, integrative -omics, NGS, microenvironment, RNA sequencing, molecular interactions, pathogenesis, pathways
Monday, December 7, 2020: 1:30 PM-3:00 PM
Moderators:
and Ella R Thompson, PhD, BSc, University of Melbourne
Disclosures:
No relevant conflicts of interest to declare.
1:30 PM

Andy G.X. Zeng, BSc1,2, Amanda Mitchell, PhD1*, Oleksandr Galkin, PhD1*, Jean C.Y. Wang, MD, PhD1,3, James A. Kennedy, MD PhD1,4 and John E. Dick, PhD, FRS2,5

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
3Department of Medicine, University of Toronto, Toronto, ON, Canada
4Sunnybrook Health Sciences Centre, Toronto, ON, Canada
5Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada

1:45 PM

Benjamin J. Huang, MD1,2*, Jenny L. Smith, MSc, MEd3*, Rhonda E. Ries, MA3*, Amanda R. Leonti, MS4*, Erin Lynn Crowgey, PhD5*, Scott N. Furlan, MD6*, Timothy Shaw, PhD7*, Lisa Wei, BS8, Yi-Cheng Wang, MS9*, Robert B. Gerbing, MA9*, Todd A. Alonzo, PhD9,10*, Todd M. Cooper, DO11, Edward A. Kolb, MD12, Xiaotu Ma, PhD13*, Jason E Farrar, MD14, Timothy Junius Triche Jr., PhD15 and Soheil Meshinchi, MD, PhD16,17

1Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
2Department of Pediatrics, University of California, San Francisco, San Francisco, CA
3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
4Clinical Research Division, Fred Hutchinson Cancer Research Center, Mountlake Terrace, WA
5Alfred I. duPont Hospital for Children, Wilmington, DE
6Fred Hutchinson Cancer Research Center, Seattle, WA
7Computational Biology, St. Jude Children's Hospital, Memphis, TN
8Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada
9Children's Oncology Group, Monrovia, CA
10Department of Preventive Medicine, University of Southern California, Monrovia, CA
11Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA
12Division of Oncology, Nemours Alfed I. duPont Hospital For Children, Wilmington, DE
13Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN
14University of Arkansas For Medical Sciences, Little Rock, AR
15Van Andel Research Institute, Grand Rapids, MI
16Department of Pediatrics, University of Washington, Seattle, WA
17Clinical Research Division, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA

2:00 PM

Hussein A Abbas, MD, PhD1, Dapeng Hao2*, Katarzyna Tomczak, PhD3*, Praveen Barrodia2*, Jin S. Im4, Patrick K Reville, MD5, Zoe Alaniz6*, Wei Wang, MD, PhD7*, Ruiping Wang, PhD8*, Feng Wang, PhD8*, Koichi Takahashi, MD, PhD8, Jing Ning, PhD9*, Maomao Ding10*, Jairo A. Matthews11*, Latasha Little, BS12*, Jianhua Zhang, PhD2*, Sreyashi Basu, PhD13*, Courtney D. DiNardo, MD, MSc14, Tapan M. Kadia, MD15, Farhad Ravandi, MBBS16, Gautam Borthakur, MD17, Marina Konopleva, MD, PhD18, Guillermo Garcia-Manero, MD17, Michael R Green, PhD19, Gheath Alatrash20, Padmanee Sharma21*, James P Allison, PhD13*, Steven M. Kornblau, MD22, Kunal Rai2*, Linghua Wang, PhD8*, P Andrew Futreal, PhD2* and Naval Daver, MD23

1Division of Cancer Medicine, Medical Oncology Fellowship, UT M. D. Anderson Cancer Center, Houston, TX
2Department of Genomic Medicine, UT M. D. Anderson Cancer Center, Houston, TX
3Department of Translational Molecular Pathology, UT M. D. Anderson Cancer Center, Houston, TX
4Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
5Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
6Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Hematopathology, UT M. D. Anderson Cancer Center, Houston, TX
8Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Biostatistics, UT M. D. Anderson Cancer Center, Houston, TX
11Department of Leukemia, UT M. D. Anderson Cancer Center, Houston, TX
12Department of Genomics Medicine, UT M. D. Anderson Cancer Center, Houston, TX
13Department of Immunology, UT M. D. Anderson Cancer Center, Houston, TX
14Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
15Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
16Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
17Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
18Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
19Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
20Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
21Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
22Department of Stem Cell Transplantation, M.D. Anderson Cancer Center University of Texas, Houston, TX
23Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX

2:15 PM

Suruchi Pacharne1*, Oliver M. Dovey, PhD2*, Jonathan L Cooper3*, Muxin Gu3*, Vijay Baskar, PhD4*, Mathias J Friedrich5*, Malgorzata Gozdecka, PhD6*, Sandeep S Rajan, PhD7*, Etienne De Braekeleer, PhD, MSc4*, Maxim Barenboim8*, Grace Collord9*, Hannes Postingl, PhD9*, Ruben Bautista9*, Milena Mazan, PhD10*, Roland Rad, Prof., MD11*, Konstantinos Tzelepis3*, Penny Wright12* and George S. Vassiliou, MD, PhD, FRCPath, MRCP13*

1WELLCOME TRUST SANGER INSTITUTE, Cambridgeshire, United Kingdom
2Wellcome Trust Sanger Institute, Cambridge, United Kingdom
3Wellcome Sanger Institute, Cambridge, United Kingdom
4Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
5Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
6Haematological Cancer Genetics, Wellcome Sanger Institute, Cambridge, ENG, United Kingdom
7UK Dementia Research Institute at the University of Cambridge, Cambridge, United Kingdom
8, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
9Wellcom Sanger Institute, Cambridge, United Kingdom
10Selvita S.A., Krakow, Poland
11Institute of Molecular Oncology and Functional Genomics, Technical University of Munich, Munich, Germany
12Cambridge University Hospitals NHS Trust, Cambridge, GBR
13Wellcome Trust Sanger Institute, Cambridge, ENG, United Kingdom

2:30 PM

Gail J. Roboz, MD1, Farhad Ravandi, MBBS2, Andrew H Wei, MBBS, PhD3,4, Hervé Dombret, MD5,6, Hartmut Döhner7, Felicitas Thol8, Maria Teresa Voso, MD9, Andre C. Schuh10, Kimmo Porkka11,12, Ignazia La Torre13*, Barry Skikne, MD14,15*, Keshava Kumar, PhD15*, Qian Dong, DrPH15*, C.L. Beach, PharmD15*, Alberto Risueño16*, Daniel Lopes de Menezes, PhD15* and Gert Ossenkoppele, MD, PhD17*

1Weill Medical College of Cornell University New York-Presbyterian Hospital, New York, NY
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3The Alfred Hospital, Melbourne, Australia
4Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
5Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris, France
6Institut de Recherche Saint Louis, Université de Paris, Paris, France
7Ulm University Hospital, Ulm, Germany
8Medizinische Hochschule Hannover, Hannover, Germany
9University of Rome Tor Vergata, Rome, Italy
10Princess Margaret Cancer Centre, Toronto, ON, Canada
11iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
12Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
13Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland
14Kansas University Medical Center, Kansas City, KS
15Bristol Myers Squibb, Princeton, NJ
16BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol Myers Squibb Company, Seville, Spain
17Amsterdam UMC, Location VU University Medical Center, Amsterdam, Netherlands

2:45 PM

Kunhwa Kim, MD MPH1*, Abhishek Maiti, MBBS2, Tapan M. Kadia, MD1, Farhad Ravandi, MBBS1, Naval Daver, MD1, Naveen Pemmaraju, MD3, Gautam Borthakur, MD2, Prithviraj Bose, MD1, Ghayas C. Issa, MD2, Nicholas J. Short, MD1, Musa Yilmaz, MD2, Yesid Alvarado, MD4, Alessandra Ferrajoli, MD1, Elias Jabbour, MD2, Nitin Jain, MD2, Maro Ohanian, DO2*, Koichi Takahashi, MD, PhD1, Philip A. Thompson, MB, MS5, Caitlin R. Rausch, PharmD6*, Kathryn Montalbano2*, Sherry A. Pierce, BSN, BA1*, Keyur P. Patel, MBBS, PhD7, Guillermo Garcia-Manero, MD1, Hagop M. Kantarjian, MD2, Courtney D. DiNardo, MD, MSc1 and Marina Konopleva, MD, PhD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
3University of Texas, MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
6Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH